Human evidence record · Menotropins (human menopausal gonadotropin)
Highly purified hMG versus recombinant FSH in predicted high responders
Fresh ongoing pregnancy was noninferior; cumulative live-birth rates were similar.
Quick read
Human evidence record
What this study tells us
Participants were assigned to groups by chance, which helps reduce selection bias. The exact comparator, blinding, population and endpoint still matter when judging the result.
Who was studied?
Women predicted to be high ovarian responders
How many?
n=620
What happened?
Fresh ongoing pregnancy was noninferior; cumulative live-birth rates were similar.
What stops us overclaiming?
Population-specific fertility protocol; cannot be extrapolated outside specialist reproductive care.
Need help with terms such as randomized, placebo, endpoint or sample size? Open the glossary →
Key result
Fresh ongoing pregnancy was noninferior; cumulative live-birth rates were similar.
Study details
Study designRandomized, assessor-blinded, parallel-group noninferiority trial
PopulationWomen predicted to be high ovarian responders
Sample size620
RouteInjection
Regimen / exposureControlled ovarian stimulation with HP-hMG or recombinant FSH
DurationART cycle + transfers within 6 months
ComparatorRecombinant FSH
Primary endpoint / questionOngoing pregnancy, cumulative live birth, OHSS and pregnancy loss
Safety resultHP-hMG was associated with lower OHSS and lower early pregnancy-loss rates in this high-responder population.
Key limitationsPopulation-specific fertility protocol; cannot be extrapolated outside specialist reproductive care.
Registry / identifierPMID 32416978 / NCT02554279